Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections
Artikel i vetenskaplig tidskrift, 2022
In this post-hoc analysis of data from a randomised clinical trial, we compared the effect of liraglutide to placebo on markers of insulin secretion in persons with type 2 diabetes treated with multiple daily insulin injections. Liraglutide increased insulin secretion, measured by C-peptide, by 19% after 24 weeks of treatment.
Clinical trial registration: EudraCT 2012-001941-42.
GLP-1 analogues
Multiple daily insulin injections
Insulin secretion
Type 2 diabetes mellitus
Författare
Klara Westman
Göteborgs universitet
NU-sjukvården
Henrik Imberg
Statistiska Konsultgruppen
Chalmers, Matematiska vetenskaper, Tillämpad matematik och statistik
Magnus O. Wijkman
Linköpings universitet
Irl B. Hirsch
School of Medicine
J. Tuomilehto
Helsingin Yliopisto
National Institute for Health and Welfare
King Abdulaziz University
S. Dahlqvist
Göteborgs universitet
NU-sjukvården
Marcus Lind
Göteborgs universitet
NU-sjukvården
Journal of Diabetes and its Complications
1056-8727 (ISSN) 1873460x (eISSN)
Vol. 36 3 108110Ämneskategorier
Endokrinologi och diabetes
Annan klinisk medicin
Neurologi
DOI
10.1016/j.jdiacomp.2021.108110
PubMed
35101325